# Scenario Analysis Results (Table 9)

Scenario analysis results showing cost-effectiveness under different assumptions.

| Country   | Scenario                     | Description                    | Strategy   | Mean_NMB   | Mean_Inc_Cost   |   Mean_Inc_QALY | Prob_Cost_Effective   |
|:----------|:-----------------------------|:-------------------------------|:-----------|:-----------|:----------------|----------------:|:----------------------|
| AU        | Base Case                    | Base case assumptions          | Ketamine   | $-3,569    | $-5,600         |          -0.183 | 28.5%                 |
| AU        | Base Case                    | Base case assumptions          | Esketamine | $-12,783   | $-1,600         |          -0.288 | 1.5%                  |
| AU        | Base Case                    | Base case assumptions          | Psilocybin | $-25,090   | $7,000          |          -0.362 | 0.4%                  |
| AU        | Optimistic                   | Higher efficacy, lower costs   | Ketamine   | $-9,273    | $-4,480         |          -0.275 | 13.9%                 |
| AU        | Optimistic                   | Higher efficacy, lower costs   | Esketamine | $-20,295   | $-1,280         |          -0.432 | 1.0%                  |
| AU        | Optimistic                   | Higher efficacy, lower costs   | Psilocybin | $-32,734   | $5,600          |          -0.543 | 1.1%                  |
| AU        | Pessimistic                  | Lower efficacy, higher costs   | Ketamine   | $862       | $-7,280         |          -0.128 | 61.4%                 |
| AU        | Pessimistic                  | Lower efficacy, higher costs   | Esketamine | $-7,988    | $-2,080         |          -0.201 | 2.9%                  |
| AU        | Pessimistic                  | Lower efficacy, higher costs   | Psilocybin | $-21,763   | $9,100          |          -0.253 | 0.1%                  |
| AU        | High Cost Scenario           | All treatment costs 50% higher | Ketamine   | $-769      | $-8,400         |          -0.183 | 48.8%                 |
| AU        | High Cost Scenario           | All treatment costs 50% higher | Esketamine | $-11,983   | $-2,400         |          -0.288 | 2.3%                  |
| AU        | High Cost Scenario           | All treatment costs 50% higher | Psilocybin | $-28,590   | $10,500         |          -0.362 | 0.1%                  |
| AU        | Low Efficacy Scenario        | 40% lower treatment efficacy   | Ketamine   | $99        | $-5,600         |          -0.11  | 54.5%                 |
| AU        | Low Efficacy Scenario        | 40% lower treatment efficacy   | Esketamine | $-7,030    | $-1,600         |          -0.173 | 2.5%                  |
| AU        | Low Efficacy Scenario        | 40% lower treatment efficacy   | Psilocybin | $-17,854   | $7,000          |          -0.217 | 0.1%                  |
| AU        | Societal Perspective         | Includes societal benefits     | Ketamine   | $-4,129    | $-5,040         |          -0.183 | 24.2%                 |
| AU        | Societal Perspective         | Includes societal benefits     | Esketamine | $-12,943   | $-1,440         |          -0.288 | 1.5%                  |
| AU        | Societal Perspective         | Includes societal benefits     | Psilocybin | $-24,390   | $6,300          |          -0.362 | 0.4%                  |
| AU        | Short Time Horizon (2 years) | 2-year time horizon            | Ketamine   | $-1,735    | $-5,600         |          -0.147 | 38.6%                 |
| AU        | Short Time Horizon (2 years) | 2-year time horizon            | Esketamine | $-9,907    | $-1,600         |          -0.23  | 1.8%                  |
| AU        | Short Time Horizon (2 years) | 2-year time horizon            | Psilocybin | $-21,472   | $7,000          |          -0.289 | 0.4%                  |
| AU        | Long Time Horizon (10 years) | 10-year time horizon           | Ketamine   | $-5,403    | $-5,600         |          -0.22  | 22.0%                 |
| AU        | Long Time Horizon (10 years) | 10-year time horizon           | Esketamine | $-15,660   | $-1,600         |          -0.345 | 1.5%                  |
| AU        | Long Time Horizon (10 years) | 10-year time horizon           | Psilocybin | $-28,707   | $7,000          |          -0.434 | 0.4%                  |
| NZ        | Base Case                    | Base case assumptions          | Ketamine   | $-3,713    | $-5,200         |          -0.178 | 27.5%                 |
| NZ        | Base Case                    | Base case assumptions          | Esketamine | $-10,281   | $-4,000         |          -0.286 | 4.6%                  |
| NZ        | Base Case                    | Base case assumptions          | Psilocybin | $-24,497   | $7,000          |          -0.35  | 0.8%                  |
| NZ        | Optimistic                   | Higher efficacy, lower costs   | Ketamine   | $-9,210    | $-4,160         |          -0.267 | 13.5%                 |
| NZ        | Optimistic                   | Higher efficacy, lower costs   | Esketamine | $-18,222   | $-3,200         |          -0.428 | 1.8%                  |
| NZ        | Optimistic                   | Higher efficacy, lower costs   | Psilocybin | $-31,845   | $5,600          |          -0.525 | 1.5%                  |
| NZ        | Pessimistic                  | Lower efficacy, higher costs   | Ketamine   | $521       | $-6,760         |          -0.125 | 57.7%                 |
| NZ        | Pessimistic                  | Lower efficacy, higher costs   | Esketamine | $-4,797    | $-5,200         |          -0.2   | 15.6%                 |
| NZ        | Pessimistic                  | Lower efficacy, higher costs   | Psilocybin | $-21,348   | $9,100          |          -0.245 | 0.2%                  |
| NZ        | High Cost Scenario           | All treatment costs 50% higher | Ketamine   | $-1,113    | $-7,800         |          -0.178 | 45.1%                 |
| NZ        | High Cost Scenario           | All treatment costs 50% higher | Esketamine | $-8,281    | $-6,000         |          -0.286 | 9.7%                  |
| NZ        | High Cost Scenario           | All treatment costs 50% higher | Psilocybin | $-27,997   | $10,500         |          -0.35  | 0.4%                  |
| NZ        | Low Efficacy Scenario        | 40% lower treatment efficacy   | Ketamine   | $-148      | $-5,200         |          -0.107 | 51.0%                 |
| NZ        | Low Efficacy Scenario        | 40% lower treatment efficacy   | Esketamine | $-4,569    | $-4,000         |          -0.171 | 11.7%                 |
| NZ        | Low Efficacy Scenario        | 40% lower treatment efficacy   | Psilocybin | $-17,498   | $7,000          |          -0.21  | 0.2%                  |
| NZ        | Societal Perspective         | Includes societal benefits     | Ketamine   | $-4,233    | $-4,680         |          -0.178 | 23.7%                 |
| NZ        | Societal Perspective         | Includes societal benefits     | Esketamine | $-10,681   | $-3,600         |          -0.286 | 3.8%                  |
| NZ        | Societal Perspective         | Includes societal benefits     | Psilocybin | $-23,797   | $6,300          |          -0.35  | 0.9%                  |
| NZ        | Short Time Horizon (2 years) | 2-year time horizon            | Ketamine   | $-1,931    | $-5,200         |          -0.143 | 36.6%                 |
| NZ        | Short Time Horizon (2 years) | 2-year time horizon            | Esketamine | $-7,425    | $-4,000         |          -0.229 | 7.0%                  |
| NZ        | Short Time Horizon (2 years) | 2-year time horizon            | Psilocybin | $-20,997   | $7,000          |          -0.28  | 0.5%                  |
| NZ        | Long Time Horizon (10 years) | 10-year time horizon           | Ketamine   | $-5,496    | $-5,200         |          -0.214 | 21.6%                 |
| NZ        | Long Time Horizon (10 years) | 10-year time horizon           | Esketamine | $-13,138   | $-4,000         |          -0.343 | 3.4%                  |
| NZ        | Long Time Horizon (10 years) | 10-year time horizon           | Psilocybin | $-27,996   | $7,000          |          -0.42  | 1.1%                  |